# Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium

> **NCT02072928** · — · COMPLETED · sponsor: **Allergan** · enrollment: 55 (actual)

## Conditions studied

- Urinary Incontinence

## Interventions

- **BIOLOGICAL:** botulinum toxin Type A

## Key facts

- **NCT ID:** NCT02072928
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-28
- **Primary completion:** 2015-09-30
- **Final completion:** 2015-09-30
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2017-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02072928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02072928, "Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02072928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*